Immunovia is focused on revolutionizing blood based diagnosis and improving survival rates for the patients with complex diseases.
IMMray™ PanCan-d is the first blood-based test dedicated to early detection of pancreatic cancer. It is exclusively available as a laboratory developed test (LDT) from Immunovia, Inc., Marlborough, USA.
About us
Immunovia is a diagnostic company developing and commercializing highly accurate blood tests based on IMMray™, Immunovia’s proprietary platform which provides antibody biomarker microarray analysis for early detection of cancer and autoimmune diseases. In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts. The IMMray™ PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see www.immunoviainc.com. European launch plan will be communicated during the second half of 2021. Immunovia has initiated since 2016 a prospective clinical validation program for high risk groups for pancreatic cancer involving 30 hospitals and over 10,000 patients from USA and Europe.
Immunovia Q2 Report 2021 presentation from August 19th, 2021 with CEO Patrik Dahlen; Medical Director Dr. Thomas King and Sr. Marketing Director US Cindy Callahan
August 2021
Immunovia AB published the company’s Interim Report January–June 2021 on Thursday, August 19, 2021, at 4.00 p.m. CET.
Place: Stockholm, Sweden
Place: Immunovia website
Place: Denmark
